Novartis AG (ADR) 

(Public, NYSE:NVS)   Watch this stock   
Find more results for NVS
Jan 26, 2010
Full Year 2009 Novartis Earnings Release - 6:00AM EST - Add to calendar
Dec 9, 2009
Novartis Investor Event : Oncology and Pipeline Update - 5:30AM EST - Add to calendar
Oct 22, 2009
Q3 2009 Novartis Corporation Earnings Conference Call
Oct 22, 2009
Q3 2009 Novartis Corporation Earnings Release
Sep 22, 2009
NOVARTIS at UBS Global Life Sciences Conference
Sep 14, 2009
NOVARTIS at Morgan Stanley Global Healthcare Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 18.71% 19.17%
Operating margin 23.33% 20.65%
EBITD margin - 28.96%
Return on average assets 9.68% 10.62%
Return on average equity 16.21% 16.33%
Employees 96,717 -

Address

Lichtstrasse 35
Basel, 4022
Switzerland

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Novartis AG (ADR) discussed on blogs

Ranking 300+ Large Cap Stocks by Cash Flow per Share - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 6 hours ago
Ranking Healthcare Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 19, 2009
Why Did Buffett Buy Glaxo SmithKline and Kraft? -- Seeking Alpha - Dickie Paria - SeekingAlpha.com: Home Page - Apr 10, 2008

Novartis AG (ADR) discussions

  View all discussions »

Description

Novartis AG, incorporated on February 29, 1996, is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare products. The Company’s healthcare solutions portfolio includes medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products. Its businesses are divided on a worldwide basis into the four operating divisions: Pharmaceuticals, which comprises brand-name patented pharmaceuticals; Vaccines and Diagnostics, which focuses on human vaccines and blood-testing diagnostics; Sandoz, which consists generic pharmaceuticals, and Consumer Health, which includes over-the-counter medicines, animal health medicines, and contact lenses and lens-care products. It operates in approximately 140 countries. In September 2009, Novartis AG announced that its Sandoz division has completed the acquisition of EBEWE Pharma's specialty generic injectables business.

Officers and directors

Daniel L. Vasella M.D.
Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation - Reuters
Joseph Jimenez
CEO - Pharmaceuticals Division
Bio & Compensation - Reuters
Joerg Reinhardt Ph.D.
Chief Operating Officer
Age: 52
Bio & Compensation - Reuters
Thomas Werlen Ph.D.
General Counsel
Age: 43
Bio & Compensation - Reuters
Juergen Brokatzky-Geiger
Head - Human Resources
Portrait. Age: 57
Bio & Compensation - Reuters
Mark C. Fishman M.D.
Member - Executive Committee
Age: 57
Bio & Compensation - Reuters
Andreas Rummelt Ph.D.
Group Head - Quality Assurance and Technical Operations
Age: 52
Bio & Compensation - Reuters
Thomas Wellauer Ph.D.
Head - Corporate Affairs
Age: 53
Bio & Compensation - Reuters
Jonathan R. Symonds
Deputy Chief Financial Officer
Age: 50
Bio & Compensation - Reuters
Ulrich Lehner Ph.D.
Independent Non-Executive Vice Chairman of the Board, Lead Director
Age: 63
Bio & Compensation - Reuters